Reirradiation for diffuse intrinsic pontine glioma: prognostic radiomic factors at progression.

IF 2.7 3区 医学 Q3 ONCOLOGY Strahlentherapie und Onkologie Pub Date : 2024-09-01 Epub Date: 2024-05-15 DOI:10.1007/s00066-024-02241-7
Dominik Wawrzuta, Marzanna Chojnacka, Monika Drogosiewicz, Katarzyna Pędziwiatr, Bożenna Dembowska-Bagińska
{"title":"Reirradiation for diffuse intrinsic pontine glioma: prognostic radiomic factors at progression.","authors":"Dominik Wawrzuta, Marzanna Chojnacka, Monika Drogosiewicz, Katarzyna Pędziwiatr, Bożenna Dembowska-Bagińska","doi":"10.1007/s00066-024-02241-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain tumor. Radiation therapy (RT) is the standard treatment, with reirradiation considered in case of progression. However, the prognostic factors for reirradiation are not well understood. This study aims to investigate the outcomes of DIPG patients undergoing reirradiation and identify clinical and radiomic prognostic factors.</p><p><strong>Methods: </strong>We conducted a retrospective analysis of patients with DIPG who underwent reirradiation at our institution between January 2016 and December 2023. Using PyRadiomics, we extracted radiomic features of tumors at the time of progression from FLAIR MRI images and collected clinical data. We used the least absolute shrinkage and selection operator (lasso) for Cox's proportional hazard model with leave-one-out cross-validation to select optimal prognostic factors for survival after reirradiation.</p><p><strong>Results: </strong>The study included 18 patients who underwent reirradiation at first progression, receiving a total dose of 20 Gy or 24 Gy in 2‑Gy fractions. Reirradiation was well tolerated, with no severe toxicity. Most patients (78%) showed neurological improvement after treatment. Median survival after progression was 29.2 weeks. The Cox model demonstrated a concordance of 0.81 (95% CI: 0.75-0.88), revealing that tumor sphericity and structural gray-level heterogeneity in FLAIR MRI images were associated with longer survival of reirradiated patients.</p><p><strong>Conclusion: </strong>Reirradiation is a safe and effective approach for patients with DIPG. MRI-based radiomic models could be helpful in predicting survival after reirradiation.</p>","PeriodicalId":21998,"journal":{"name":"Strahlentherapie und Onkologie","volume":" ","pages":"797-804"},"PeriodicalIF":2.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11343881/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Strahlentherapie und Onkologie","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00066-024-02241-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/15 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain tumor. Radiation therapy (RT) is the standard treatment, with reirradiation considered in case of progression. However, the prognostic factors for reirradiation are not well understood. This study aims to investigate the outcomes of DIPG patients undergoing reirradiation and identify clinical and radiomic prognostic factors.

Methods: We conducted a retrospective analysis of patients with DIPG who underwent reirradiation at our institution between January 2016 and December 2023. Using PyRadiomics, we extracted radiomic features of tumors at the time of progression from FLAIR MRI images and collected clinical data. We used the least absolute shrinkage and selection operator (lasso) for Cox's proportional hazard model with leave-one-out cross-validation to select optimal prognostic factors for survival after reirradiation.

Results: The study included 18 patients who underwent reirradiation at first progression, receiving a total dose of 20 Gy or 24 Gy in 2‑Gy fractions. Reirradiation was well tolerated, with no severe toxicity. Most patients (78%) showed neurological improvement after treatment. Median survival after progression was 29.2 weeks. The Cox model demonstrated a concordance of 0.81 (95% CI: 0.75-0.88), revealing that tumor sphericity and structural gray-level heterogeneity in FLAIR MRI images were associated with longer survival of reirradiated patients.

Conclusion: Reirradiation is a safe and effective approach for patients with DIPG. MRI-based radiomic models could be helpful in predicting survival after reirradiation.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
弥漫性桥脑胶质瘤的再照射:进展期的预后放射学因素。
目的:弥漫性桥脑胶质瘤(DIPG)是一种致命的小儿脑肿瘤。放射治疗(RT)是标准治疗方法,如果病情恶化,则考虑再次放射治疗。然而,再照射的预后因素尚不十分清楚。本研究旨在调查接受再照射治疗的DIPG患者的预后情况,并确定临床和放射学预后因素:我们对2016年1月至2023年12月期间在我院接受再照射的DIPG患者进行了回顾性分析。利用PyRadiomics,我们从FLAIR MRI图像中提取了肿瘤进展时的放射学特征,并收集了临床数据。我们使用最小绝对缩小和选择算子(lasso)建立了Cox比例危险模型,并进行了一出交叉验证,以选择再照射后生存率的最佳预后因素:研究共纳入了18名患者,他们在病情首次进展时接受了再照射,总剂量为20 Gy或24 Gy,分次剂量为2 Gy。患者对再照射的耐受性良好,无严重毒性反应。大多数患者(78%)在治疗后神经功能有所改善。进展后的中位生存期为 29.2 周。Cox模型的一致性为0.81(95% CI:0.75-0.88),表明FLAIR MRI图像中肿瘤的球形性和结构灰度异质性与再照射患者的生存期延长有关:结论:对DIPG患者来说,再照射是一种安全有效的方法。结论:对 DIPG 患者进行再照射是一种安全有效的方法,基于 MRI 的放射学模型有助于预测再照射后的存活率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.70
自引率
12.90%
发文量
141
审稿时长
3-8 weeks
期刊介绍: Strahlentherapie und Onkologie, published monthly, is a scientific journal that covers all aspects of oncology with focus on radiooncology, radiation biology and radiation physics. The articles are not only of interest to radiooncologists but to all physicians interested in oncology, to radiation biologists and radiation physicists. The journal publishes original articles, review articles and case studies that are peer-reviewed. It includes scientific short communications as well as a literature review with annotated articles that inform the reader on new developments in the various disciplines concerned and hence allow for a sound overview on the latest results in radiooncology research. Founded in 1912, Strahlentherapie und Onkologie is the oldest oncological journal in the world. Today, contributions are published in English and German. All articles have English summaries and legends. The journal is the official publication of several scientific radiooncological societies and publishes the relevant communications of these societies.
期刊最新文献
[Longterm outcome of definitive radiotherapy using IMRT vs. 3D-CRT in locally advanced, inoperable non-small cell lung cancer (NSCLC)]. Non-coding RNAs modulation in breast cancer radioresponse: mechanisms and therapeutic implications. Interstitial HDR brachytherapy for anal cancer-results and quality of life. Efficacy of palliative hemostatic radiotherapy for tumor bleeding and pain relief in locally advanced pelvic gynecological malignancies. Friedrich Dessauer-reflections on his political and personal sacrifices : In reply to: Benzaquen et al. "Friedrich Dessauer (1881-1963): The forgotten medical physicist, politician, and philosopher".
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1